



Main Nav



United Therapeutics  
CORPORATION

Hero Carousel



Image

[Image / Images]

Tt



[UTC Intro message]

Feature Text

*Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.*

*For the most complete and up-to-date information on United*



## Disease Ed Definitions

# Pulmonary Arterial Hypertension (PAH) WHO Group 1

## Definition

WHO Group 1 pulmonary hypertension is also known as pulmonary arterial hypertension (PAH) and is distinguished by high blood pressure that specifically occurs in the vessels that supply the lungs.



## Products



**REMODULIN<sup>®</sup>**  
(treprostinil) Injection

**TYVASO<sup>®</sup>**  
(treprostinil) INHALATION  
SOLUTION

**O.**  
**orenitram<sup>®</sup>**  
treprostinil  
EXTENDED-RELEASE TABLETS

**adcirca<sup>®</sup>**  
tadalafil tablets 20mg



**Important Safety Information**

Prescribing Information

[Remodulin.com](https://www.remodulin.com)

## Remodulin<sup>®</sup> (treprostinil) Injection

### Important Safety Information

### Warnings and Precautions

common adverse events ( $\geq 3\%$  more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).

### Drug Interactions

- Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

### Specific Populations

- In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
- Safety and effectiveness of Remodulin in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

### Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISlhcpOct19

**Please see accompanying [Full Prescribing Information](#) for Remodulin.**

**For additional information, visit [www.remodulin.com](http://www.remodulin.com) or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).**